JPS6260106B2 - - Google Patents
Info
- Publication number
- JPS6260106B2 JPS6260106B2 JP55035217A JP3521780A JPS6260106B2 JP S6260106 B2 JPS6260106 B2 JP S6260106B2 JP 55035217 A JP55035217 A JP 55035217A JP 3521780 A JP3521780 A JP 3521780A JP S6260106 B2 JPS6260106 B2 JP S6260106B2
- Authority
- JP
- Japan
- Prior art keywords
- suppressor
- cells
- cell
- carrier
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 210000001124 body fluid Anatomy 0.000 claims description 10
- 239000010839 body fluid Substances 0.000 claims description 10
- 210000003743 erythrocyte Anatomy 0.000 claims description 10
- 230000001506 immunosuppresive effect Effects 0.000 claims description 10
- 230000001715 anti-suppressor Effects 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 6
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 6
- 108010074605 gamma-Globulins Proteins 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 229920003002 synthetic resin Polymers 0.000 claims description 4
- 239000000057 synthetic resin Substances 0.000 claims description 4
- 239000002657 fibrous material Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims 2
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 210000005008 immunosuppressive cell Anatomy 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- -1 polyoxymethylene Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3521780A JPS56130160A (en) | 1980-03-19 | 1980-03-19 | Device for removing immunity inhibiting cell in body fluid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3521780A JPS56130160A (en) | 1980-03-19 | 1980-03-19 | Device for removing immunity inhibiting cell in body fluid |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15922986A Division JPS62123131A (ja) | 1986-07-07 | 1986-07-07 | 抗サプレツサ−ｔ細胞抗体およびその製法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56130160A JPS56130160A (en) | 1981-10-12 |
| JPS6260106B2 true JPS6260106B2 (enrdf_load_html_response) | 1987-12-15 |
Family
ID=12435671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3521780A Granted JPS56130160A (en) | 1980-03-19 | 1980-03-19 | Device for removing immunity inhibiting cell in body fluid |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS56130160A (enrdf_load_html_response) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8637084B2 (en) * | 2009-07-14 | 2014-01-28 | Asahi Kasei Medical Co., Ltd. | Treatment method for epithelial cancerous organism |
| US9127250B2 (en) | 2011-03-29 | 2015-09-08 | Shiga University Of Medical Science | Immunosuppressive cell-capturing material and immunosuppressive cell-capturing column |
| JP5922373B2 (ja) * | 2011-10-31 | 2016-05-24 | 日機装株式会社 | 血液吸着器の製造方法及び製造装置 |
| BR112020003093A2 (pt) * | 2017-09-08 | 2020-08-25 | Toray Industries, Inc. | material de adsorção para leucócitos imunossupressores, e, coluna de adsorção |
| WO2019073992A1 (ja) * | 2017-10-11 | 2019-04-18 | 国立大学法人京都大学 | 抗体修飾フィルター |
-
1980
- 1980-03-19 JP JP3521780A patent/JPS56130160A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56130160A (en) | 1981-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0276342B1 (en) | Method for treating plasma and products thereof | |
| Bieber et al. | Human antibodies accelerate the rate of remyelination following lysolecithin‐induced demyelination in mice | |
| US5122112A (en) | Antigen-specific removal of circulating immune complexes | |
| US5147289A (en) | Non-specific immune system enhancement | |
| US4464165A (en) | Material and method for removing immunoglobulins from whole blood | |
| Augustin et al. | Human reagins to grass pollens and moulds: their purification and physico-chemical characterization | |
| EP0313378A2 (en) | Methods and compositions for transient elimination of humoral immune antibodies | |
| Grohsman et al. | The Immune Recognition of Ta3 Tumors, Its Facilitation by Endotoxin, and Abrogation by Abcites Fluid | |
| EP0421380B1 (en) | Tumor-lysing cell inducer, method for inducing tumor-lysing cell and device for inducing tumor-lysing cell | |
| Bentwich et al. | Antigenic changes on the surface of lymphocytes from patients with chronic lymphocytic leukemia | |
| JPS6260106B2 (enrdf_load_html_response) | ||
| Drew et al. | Autoimmune cytotoxic granulocyte antibodies in normal persons and various diseases | |
| EP0272792B1 (en) | Antigen-specific removal of circulating immune complexes | |
| Miller et al. | Thymic dysplasia (“Swiss agammaglobulinemia”): II. Morphologic and functional observations | |
| US4409330A (en) | Material and method for removing immunoglobulins from whole blood | |
| Edelson | Round cells of the epidermis: clues from studies on neoplastic lymphocytes of cutaneous T cell lymphoma | |
| JPS62123131A (ja) | 抗サプレツサ−ｔ細胞抗体およびその製法 | |
| Hornung et al. | The Use of Human F (ab′) 2 Fragments as Blocking Agents in the Mixed Lymphocyte Reaction | |
| Haas et al. | Techniques for separation and selection of antigen specific lymphocytes | |
| Sjöberg et al. | Conditions for induction of specific and polyclonal antibody production by Cowan 1 bacteria and by pokeweed mitogen | |
| Amemiya et al. | The nature of antiplatelet activity in antilymphoblast ALG: with special reference to crossreacting antibody, immunochemical characterization, and Coombs' positive thrombocytopenia in ALG-treated renal recipients | |
| KHOSRAVI et al. | Relationship of melanoma-Associated antigens to histocompatibility antigen and β-2 microglobulin in material spontaneously shed by cultured human melanoma cells | |
| Moore et al. | Purified roswell park cultured antilymphocytie globulin RPMI‐CALG: Preparation and clinical trial | |
| JPS59116224A (ja) | 免疫反応を抑制する組成物およびその製法 | |
| Petrescu et al. | Humoral antibody production following primary and secondary immunization in rabbits treated with thiamphenicol and chloramphenicol |